Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 13, 1269 (2007)
doi:10.1038/nm1107-1269
New law gives FDA more influence to monitor drug safety
Meredith Wadman1
- Washington, DC
When the US Food and Drug Administration (FDA) announced on 16 October that the diabetes drug Byetta may cause pancreatitis, a serious and sometimes fatal side effect, most scientists could have been forgiven for being taken by surprise.There's not a whiff of pancreatitis in the detailed results from the 19 clinical trials of Byetta in two publicly available databases—one launched and maintained by the drug industry and another by Eli Lilly, which, together with Amylin Pharmaceuticals, markets Byetta.
To read this story in full you will need to login or make a payment (see right).
